Application of neuroprotectors in severe brain injuries
https://doi.org/10.20538/1682-0363-2011-5-36-40
Abstract
Blood concentration of protein S100 was been decreased with choline-liked neuroprotectors citicoline and choline alfoscerate in clinical trial 52 patients in early day after stroke. Concentration of neuron-specific enolase was been decreased with three month mildronat therapy in blood of 16 patients with traumatic brain injury. Neuroprotective therapy has stabilization of blood-brain barrier as result.
About the Authors
O. Ye. Vaizova
Siberian State Medical University
Russian Federation
Russian Federation
N. A. Zautner
Siberian State Medical University
Russian Federation
Russian Federation
V. M. Alifirova
Siberian State Medical University
Russian Federation
Russian Federation
D. V. Kolmakov
Siberian State Medical University
Russian Federation
Russian Federation
Ye. L. Golovina
Siberian State Medical University
Russian Federation
Russian Federation
A. S. Molodykh
Siberian State Medical University
Russian Federation
Russian Federation
References
1. Галиева Г.Ю., Попонникова Т.В., Федосеева И.Ф. Диагностическое и прогностическое значение нейронспецифиче-ской енолазы и белка S100 при клещевых нейроинфекциях у детей//Бюл. cиб. медицины. 2008. Т. 7, прил. 1. С. 204-207.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. и др. Эпидемиология инсульта в России//Consilium medicum. 2003. Т. 5, ¹ 5. C. 3-5.
3. Карякина Г.М., Надеждина М.В., Хинко М.А. Нейронспе-цифическая енолаза как индикатор поражения мозговой ткани при ишемических инсультах//Неврол. вестн. 2007. Т. 39, ¹ 1. C. 41-44.
4. Сергеев Д.В., Пирадов М.А. Нейропротекция -стратегическое направление в лечении ишемического инсульта//Рус. мед. журн. 2010. Т. 18, ¹ 8. C. 441-445.
5. Таранушенко Т.Е., Окунева О.С., Демьянова И.М. Уровень белков нейрональной и глиальной природы в крови новорожденных при церебральной ишемии//Педиатрия. 2010. Т. 80, ¹ 1. С. 25-31.
6. Abraha H.D., Buttenvoiih R.G., Sherwood R.A. Serum S-100 protein, relationship to clinical outcome in acute stroke//Ann. Clin. Biochem. 1997. V. 34, ¹ 4. P. 366-370.
7. Adibhatla R.M., Hatcher J.F., Dempsey R.J. Effects of citi-coline on phospholipid and glutathione levels in transient cerebral ischemia//Stroke. 2001. V. 32, ¹ 12. P. 2376-2381.
8. Alvarez-Sabin J., Roman G.C. Citicoline in vascular cognitive impairment and vascular dementia after stroke//Stroke. 2011. V. 42. S40-S43.
9. Clark W.M., Williams B.J., Selzer K.A. et al. A random ized efficacy trial of citicoline in patients with acute ischemic stroke//Stroke. 1999. V. 30, ¹ 13. P. 2592-2597.
10. Davalos A., Castillo J., Alvarez-Sabin J. et al. Oral citi-coline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials//Stroke. 2002. V. 33, ¹ 14. P. 2850-2857.
11. Guidelines for management of ischemic stroke and transient isch-emic attack//Cerebrovas. Dis. 2008. V. 25, ¹ 3. P. 457-507.
12. Jaudzems K., Kuka J., Gutsaits A. et al. Inhibition of car-nitine acetyltransferase by mildronate, a regulator of energy metabolism//J. Enzyme Inhib. Med. Chem. 2009. V. 24, ¹ 6. P. 1269-1275.
13. Martens P., Raabe A., Johnsson P. Serum S-100 and neuron-spe cific enolase for prediction of regaining consciousness after global cerebral ischemia//Stroke. 1998. V. 29, ¹ 12. P. 2363-2366.
14. Oshitari T., Yoshida-Hata N., Yamamoto S. Effect of neu-rotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose//Brain Res. 2010. V. 1346, ¹ 30. P. 43-51.
15. Pupure J., Isajevs S., Skapare E. et al. Neuroprotective properties of mildronate, a mitochondria-targeted small molecule//Neurosci. Lett. 2011. V. 412, ¹ 2. P. 100-105.
Review
For citations:
Vaizova O.Ye., Zautner N.A., Alifirova V.M., Kolmakov D.V., Golovina Ye.L., Molodykh A.S. Application of neuroprotectors in severe brain injuries. Bulletin of Siberian Medicine. 2011;10(5):36-40. (In Russ.) https://doi.org/10.20538/1682-0363-2011-5-36-40
Views:
633
Email this article 